Syndax unveils mutant-selective EGFR inhibitor SNDX-4321, targets IND filing by end-2026

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

SNDX

0.00
  • Syndax unveiled two new pipeline programs at an R&D event, expanding beyond its late-stage revumenib and axatilimab franchises.
  • Introduced SNDX-4321, a mutant-selective allosteric EGFR inhibitor for EGFR-mutated NSCLC; IND filing targeted by end-2026; Phase 1 start in 2027.
  • Selected SNDX-62122, a next-generation menin inhibitor, for myelofibrosis; IND filing expected in 2027; Phase 1 planned in 2027.
  • Axatilimab Phase 2 trial in idiopathic pulmonary fibrosis remains on track for topline data in 4Q26.
  • Revumenib proof-of-principle Phase 1/2 study in myelofibrosis planned to start in 4Q26; initial data expected in 2H27.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140800PRIMZONEFULLFEED9761594) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.